GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » Graham Number

PharmaCyte Biotech (PharmaCyte Biotech) Graham Number : $N/A (As of Jan. 2024)


View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-05-23), the stock price of PharmaCyte Biotech is $2.14. PharmaCyte Biotech's graham number for the quarter that ended in Jan. 2024 was $N/A. Therefore, PharmaCyte Biotech's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for PharmaCyte Biotech's Graham Number or its related term are showing as below:

PMCB's Price-to-Graham-Number is not ranked *
in the Biotechnology industry.
Industry Median: 2.18
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


PharmaCyte Biotech Graham Number Historical Data

The historical data trend for PharmaCyte Biotech's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech Graham Number Chart

PharmaCyte Biotech Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PharmaCyte Biotech Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PharmaCyte Biotech's Graham Number

For the Biotechnology subindustry, PharmaCyte Biotech's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech's Price-to-Graham-Number Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Price-to-Graham-Number falls into.



PharmaCyte Biotech Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

PharmaCyte Biotech's Graham Number for the fiscal year that ended in Apr. 2023 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*4.117*-0.22)
=N/A

PharmaCyte Biotech's Graham Number for the quarter that ended in Jan. 2024 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*3.266*-1.384)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaCyte Biotech  (NAS:PMCB) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

PharmaCyte Biotech's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Jan. 2024 )
=2.14/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


PharmaCyte Biotech Graham Number Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaCyte Biotech (PharmaCyte Biotech) Business Description

Traded in Other Exchanges
N/A
Address
3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. It is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb director 100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen director 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K director
Carlos Trujillo director, officer: CFO 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner director, officer: Chairman, CEO, Pres and GC 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree director, officer: Chief Science Officer 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099

PharmaCyte Biotech (PharmaCyte Biotech) Headlines